Study presented at the European Society for Medical Oncology (ESMO) Congress may mean a new way to treat patients with stage 3 lung cancer

This past week, results of some key studies were presented at a major meeting in Spain. One study, called the PACIFIC trial, could change the way that patients with stage 3 lung cancer are treated. The study showed that patients with stage 3 lung cancer who took an immunotherapy drug (durvalumab, brand name Imfinzi) after chemotherapy and radiation had a longer period of progression-free survival (16.8 months) than patients who were not treated with immunotherapy (5.6 months). The results for overall survival are not yet available. Durvalumab is a PD-L1 inhibitor that is not yet FDA approved for lung cancer. onclive.com/conference-cove...